Annual EBIT
-$29.43 M
-$1.80 M-6.51%
December 31, 2023
Summary
- As of February 8, 2025, RGLS annual earnings before interest & taxes is -$29.43 million, with the most recent change of -$1.80 million (-6.51%) on December 31, 2023.
- During the last 3 years, RGLS annual EBIT has fallen by -$15.51 million (-111.41%).
- RGLS annual EBIT is now -319.98% below its all-time high of -$7.01 million, reached on December 31, 2011.
Performance
RGLS EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$14.06 M
-$3.08 M-28.06%
September 30, 2024
Summary
- As of February 8, 2025, RGLS quarterly earnings before interest & taxes is -$14.06 million, with the most recent change of -$3.08 million (-28.06%) on September 30, 2024.
- Over the past year, RGLS quarterly EBIT has dropped by -$3.08 million (-28.06%).
- RGLS quarterly EBIT is now -1422.97% below its all-time high of -$923.00 thousand, reached on December 31, 2020.
Performance
RGLS Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$41.37 M
-$6.37 M-18.20%
September 30, 2024
Summary
- As of February 8, 2025, RGLS TTM earnings before interest & taxes is -$41.37 million, with the most recent change of -$6.37 million (-18.20%) on September 30, 2024.
- Over the past year, RGLS TTM EBIT has dropped by -$6.37 million (-18.20%).
- RGLS TTM EBIT is now -4282.31% below its all-time high of -$944.00 thousand, reached on September 30, 2011.
Performance
RGLS TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
RGLS EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -6.5% | -28.1% | -18.2% |
| 3 y3 years | -111.4% | -98.1% | -42.7% |
| 5 y5 years | +36.4% | -186.5% | -190.0% |
RGLS EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -9.2% | at low | -114.2% | at low | -53.5% | at low |
| 5 y | 5-year | -111.4% | at low | -1423.0% | at low | -204.3% | at low |
| alltime | all time | -320.0% | +63.5% | -1423.0% | +36.6% | -4282.3% | +48.7% |
Regulus Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$14.06 M(+28.1%) | -$41.37 M(+18.2%) |
| Jun 2024 | - | -$10.98 M(+30.9%) | -$35.00 M(+13.4%) |
| Mar 2024 | - | -$8.39 M(+5.5%) | -$30.87 M(+4.9%) |
| Dec 2023 | -$29.43 M(+6.5%) | -$7.95 M(+3.4%) | -$29.43 M(+4.8%) |
| Sep 2023 | - | -$7.69 M(+12.3%) | -$28.08 M(+1.1%) |
| Jun 2023 | - | -$6.84 M(-1.6%) | -$27.77 M(-0.9%) |
| Mar 2023 | - | -$6.95 M(+5.4%) | -$28.02 M(+1.4%) |
| Dec 2022 | -$27.63 M(+2.5%) | -$6.60 M(-10.5%) | -$27.63 M(-1.1%) |
| Sep 2022 | - | -$7.38 M(+3.9%) | -$27.95 M(-3.6%) |
| Jun 2022 | - | -$7.10 M(+8.1%) | -$29.00 M(+4.6%) |
| Mar 2022 | - | -$6.56 M(-5.1%) | -$27.72 M(+2.8%) |
| Dec 2021 | -$26.95 M(+93.6%) | -$6.92 M(-17.8%) | -$26.95 M(+28.6%) |
| Sep 2021 | - | -$8.42 M(+44.7%) | -$20.95 M(+54.1%) |
| Jun 2021 | - | -$5.82 M(+0.3%) | -$13.59 M(-4.7%) |
| Mar 2021 | - | -$5.80 M(+528.1%) | -$14.26 M(+2.4%) |
| Dec 2020 | -$13.92 M(-15.4%) | -$923.00 K(-12.7%) | -$13.92 M(-20.0%) |
| Sep 2020 | - | -$1.06 M(-83.7%) | -$17.39 M(-18.1%) |
| Jun 2020 | - | -$6.49 M(+18.9%) | -$21.24 M(+10.4%) |
| Mar 2020 | - | -$5.46 M(+24.2%) | -$19.23 M(+16.9%) |
| Dec 2019 | -$16.46 M(-64.5%) | -$4.39 M(-10.5%) | -$16.46 M(-18.0%) |
| Sep 2019 | - | -$4.91 M(+9.6%) | -$20.07 M(-19.1%) |
| Jun 2019 | - | -$4.48 M(+66.9%) | -$24.82 M(-26.1%) |
| Mar 2019 | - | -$2.68 M(-66.5%) | -$33.57 M(-27.5%) |
| Dec 2018 | -$46.30 M(-33.3%) | -$8.01 M(-17.1%) | -$46.30 M(-10.6%) |
| Sep 2018 | - | -$9.65 M(-27.0%) | -$51.81 M(-9.8%) |
| Jun 2018 | - | -$13.23 M(-14.2%) | -$57.41 M(-12.1%) |
| Mar 2018 | - | -$15.42 M(+14.1%) | -$65.32 M(-5.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2017 | -$69.38 M(-14.0%) | -$13.51 M(-11.4%) | -$69.38 M(-8.0%) |
| Sep 2017 | - | -$15.26 M(-27.8%) | -$75.37 M(-4.7%) |
| Jun 2017 | - | -$21.13 M(+8.5%) | -$79.07 M(+0.2%) |
| Mar 2017 | - | -$19.48 M(-0.1%) | -$78.95 M(-2.1%) |
| Dec 2016 | -$80.66 M(+44.8%) | -$19.51 M(+2.9%) | -$80.66 M(+18.0%) |
| Sep 2016 | - | -$18.95 M(-9.8%) | -$68.34 M(+9.5%) |
| Jun 2016 | - | -$21.01 M(-0.8%) | -$62.40 M(-0.0%) |
| Mar 2016 | - | -$21.19 M(+194.6%) | -$62.42 M(+12.0%) |
| Dec 2015 | -$55.71 M(-1.6%) | -$7.19 M(-44.7%) | -$55.72 M(-21.2%) |
| Sep 2015 | - | -$13.01 M(-38.1%) | -$70.68 M(+4.8%) |
| Jun 2015 | - | -$21.03 M(+45.2%) | -$67.46 M(+15.5%) |
| Mar 2015 | - | -$14.48 M(-34.6%) | -$58.39 M(+3.1%) |
| Dec 2014 | -$56.64 M(+203.6%) | -$22.16 M(+126.4%) | -$56.64 M(+55.5%) |
| Sep 2014 | - | -$9.79 M(-18.2%) | -$36.41 M(+26.5%) |
| Jun 2014 | - | -$11.96 M(-6.0%) | -$28.79 M(+19.2%) |
| Mar 2014 | - | -$12.73 M(+557.8%) | -$24.15 M(+29.4%) |
| Dec 2013 | -$18.66 M(+8.6%) | -$1.94 M(-10.5%) | -$18.66 M(-21.0%) |
| Sep 2013 | - | -$2.16 M(-70.5%) | -$23.63 M(-12.6%) |
| Jun 2013 | - | -$7.32 M(+1.1%) | -$27.05 M(+21.5%) |
| Mar 2013 | - | -$7.24 M(+4.8%) | -$22.26 M(+29.6%) |
| Dec 2012 | -$17.17 M(+145.0%) | -$6.91 M(+23.7%) | -$17.17 M(+41.8%) |
| Sep 2012 | - | -$5.58 M(+120.5%) | -$12.11 M(+62.1%) |
| Jun 2012 | - | -$2.53 M(+17.6%) | -$7.47 M(+51.2%) |
| Mar 2012 | - | -$2.15 M(+16.7%) | -$4.94 M(+77.2%) |
| Dec 2011 | -$7.01 M(-54.0%) | -$1.84 M(+95.4%) | -$2.79 M(+195.4%) |
| Sep 2011 | - | -$944.00 K | -$944.00 K |
| Dec 2010 | -$15.23 M | - | - |
FAQ
- What is Regulus Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Regulus Therapeutics?
- What is Regulus Therapeutics annual EBIT year-on-year change?
- What is Regulus Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Regulus Therapeutics?
- What is Regulus Therapeutics quarterly EBIT year-on-year change?
- What is Regulus Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Regulus Therapeutics?
- What is Regulus Therapeutics TTM EBIT year-on-year change?
What is Regulus Therapeutics annual earnings before interest & taxes?
The current annual EBIT of RGLS is -$29.43 M
What is the all time high annual EBIT for Regulus Therapeutics?
Regulus Therapeutics all-time high annual earnings before interest & taxes is -$7.01 M
What is Regulus Therapeutics annual EBIT year-on-year change?
Over the past year, RGLS annual earnings before interest & taxes has changed by -$1.80 M (-6.51%)
What is Regulus Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of RGLS is -$14.06 M
What is the all time high quarterly EBIT for Regulus Therapeutics?
Regulus Therapeutics all-time high quarterly earnings before interest & taxes is -$923.00 K
What is Regulus Therapeutics quarterly EBIT year-on-year change?
Over the past year, RGLS quarterly earnings before interest & taxes has changed by -$3.08 M (-28.06%)
What is Regulus Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of RGLS is -$41.37 M
What is the all time high TTM EBIT for Regulus Therapeutics?
Regulus Therapeutics all-time high TTM earnings before interest & taxes is -$944.00 K
What is Regulus Therapeutics TTM EBIT year-on-year change?
Over the past year, RGLS TTM earnings before interest & taxes has changed by -$6.37 M (-18.20%)